See which workplaces made this year's list.

2025_GPTW_BiotechnologyPharmaceuticals_Large_Merck_US1__685d500b023fa8a02634231b_1

Employees say:&nbsp;"Senior leadership at Merck is committed to establishing a healthy work environment, and many mid-level managers set a positive example. I believe most Merck employees genuinely strive to make a meaningful impact, both within the work environment and in patient care. A good example is the various mentorship programs I have attended. Despite mentoring me being outside of their job responsibilities and not accounted for in their annual performance reviews, all my mentors have done their best to support me and provide constructive feedback."

Best Large Workplaces in Biotechnology and Pharmaceuticals

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Fortune Global 500

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 145,000 U.S. employees.

Best Workplaces_New York_Large_2025-Merck_US1__67fd6364bb07cc513ab900de_2

Employees say:"Merck is outstanding at seeing the employee as a "whole person," as a valuable resource to the company and its patients. Over the past several years, I have seen how the company has put concerted effort into ensuring that employees take time away, care for themselves, care for their families, etc. To get the best out of employees, the employees need to BE at their best. And I certainly appreciate how Merck has pivoted and built that flexibility into the rhythms, and now expectations, of employment. It truly is a great place to work. Thank you!"

35 Best Large Workplaces in New York

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Fortune 500

The top companies on our list have one thing in common: Staff largely trust leadership to see them as well-rounded people and reward them for a job well done.

Employees say: "I feel this company really invests in their people. I started out 25 years ago on a temporary assignment that was to last four days. As long as you have the drive and determination, your career at this company can make an impact and can grow significantly. They provide many tools and opportunities, but it is up to the employee to leverage them. I have a disabled husband who I have to take care of financially and physically, and this company has always been flexible and supportive, which allows me to maintain a great work-life balance and still efficiently get work done. They also support innovation, and I feel new ideas are encouraged and I have seen impact of change initiatives, by either myself, or that my team have brought up."

Fortune 100 Best Companies to Work For

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

World's Most Admired Companies

Employees say:"This is more than a company, it is a huge family! Each person, regardless of their role, education, or experience is treated equally importantly. Since our first national meeting, I have repeatedly been acknowledged and never felt unimportant. This work environment is exceptional and each of us strives to work harder and more efficient as we feel appreciated and supported."

Best Large Workplaces for Parents

GPTW_Parents_Large_2024-Merck_US1__20240918135500_1.jpg

Employees say:"Merck is outstanding at seeing the employee as a "whole person," as a valuable resource to the company and its patients. Over the past several years, I have seen how the Company has put concerted effort into ensuring that employees take time away, care for themselves, care for their families, etc. To get the best out of employees, the employees need to BE at their best. And I certainly appreciate how Merck has pivoted and built that flexibility into the rhythms. It truly is a great place to work. "

GPTW BioPharma Large 2024-Merck

Employees say:"The culture of support for the Employee Business Resource Groups creates a physical environment of care, community, and collaboration that fosters trust in both the EBRG teams as well as in the DE&amp;I journey within the greater company culture."

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 140,000 U.S. employees.

GPTW-2024-New-York-Large-Merck

Employees say:"The main thing that drives me is the sense of ethics and always putting patients first, and not profits. This makes me proud to work here and confident that everyone at the company is driven by the same north."

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

Creating a more empathetic workplace looks like staying loyal to workers, emphasizing D&I initiatives, and paying well.

100 Best Companies 2024-Merck

New Jersey–based pharmaceutical company Merck climbed 36 spots from No. 98 on last year’s Best Companies list, with about 75% of the company’s employees worldwide undergoing a pay equity study as of 2021, which grew to 90% in 2022. That 2022 study, by the way, showed that Merck had achieved over 99% pay equity for both women and men and white and non-white employees in the U.S. &nbsp;Merck’s diversity programs have worked to address gender pay disparities and representation of women in the workplace. The company’s board of directors has more gender diversity than the industry norm, consisting of 46% female representation, while women make up 33% of Merck’s executives. Merck’s Women’s Leadership Program and Emerging Women’s Leadership program provide professional development training for women employees.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

Building a culture of trust and transparency is essential to help everyone thrive, especially in rocky economic times.

100 BEST COMPANIES 2023-Merck

While Merck’s business focus revolves around using science to save lives and improve physical health, the company has made the mental health of its employees a priority as well. 
<ul> 
 	<li>Roughly 4,000 managers have been trained on how to connect their workers with well-being resources and educated on how to respond with compassion toward someone who may be struggling.</li> 
 	<li>Roughly 100 workers have completed Mental Health First Aid training and are available to help colleagues access mental health information and resources. It’s a grassroots project to reduce the stigma and raise awareness of mental health issues.</li> 
 	<li>Lyra, launched in 2021, ensures both employees and their families have quick access to high-quality evidence-based mental health care.</li> 
 	<li>Employees are provided with a membership to relaxation app Calm, as well as a flex day, time off to volunteer, and a generous parental leave program.</li> 
 	<li>“Merck shows that we are people, not just employees, with lives outside of work and honors that and promotes balancing work/home life,” said one worker.</li> 
</ul>

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 100,000 U.S. employees.

GPTW-New-York-2023-Merck_1000976-5

Employees say: 
 
"The organization operates with integrity on all levels. Merck is mission-driven and highly principled. Management genuinely cares about employees as individuals—promotes work-life balance and health and wellness, and celebrates diversity. My management listens and follows up on issues brought to their attention and consistently works to remove barriers in processes to help support me and my colleagues in my department to be successful in our jobs."

GPTW 2023 best workplaces pharma LARGE

Employees say: 
 
"The people who work here are amazing and inspiring—people push me to better myself and remind me of what is important and why we do what we do!"

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

F500-2023-069-Merck

The pharmaceutical firm that makes commonly used drugs, including HPV vaccine Gardasil, has held strong in its 69th year on the Fortune 500 list. 
<ul> 
 	<li>Merck surpassed expectations in 2022, bringing in $59.3 billion in revenue and $14.5 billion in profit.</li> 
 	<li>In April 2023, Merck announced plans to acquire Prometheus Biosciences for $10.8 billion. It is one of a few deals of its kind, but analysts say it could signal the beginning of a period of intense M&amp;A for biotech companies.</li> 
 	<li>Merck, along with Moderna, is making progress toward a cancer vaccine for melanoma patients. The immunotherapy drug Keytruda, Merck’s top seller, is part of the vaccine and was a strong growth driver.</li> 
 	<li>Sales of the COVID oral antiviral drug Lagevrio reported robust sales in 2022, but the company expects a significant slowdown in 2023.</li> 
</ul>

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

WMAC 2022 41 Merck

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

The companies on this year's list stand out for celebrating innovation, promoting cooperation, and more.

GPTW New York Large 2022-Merck

Employees say: 
 
“The number of available opportunities/modalities for personal and professional development is truly astounding. Additionally, employees have the opportunity to participate in secondments (away from their hired position) of up to 6 months to work in and learn about another functional area/role. To me, this really emphasizes our company's investment in the PERSON.” 
 
Read the Great Place to Work review .

Great-Places-to-Work-in-Biotechnology-Large-2022-Merck_1000976-3

Employees say: 
 
“The company work culture is very inclusive and compassionate. Everyone is very caring and makes new people feel welcome. It's also very easy to move around departments and working groups. They put a great focus on professional development and networking for everyone.”

Fortune's annual list dedicated to the idea that business is uniquely suited to address society’s biggest challenges.

CTW.1122.Merck Gardasil

Merck’s Gardasil is a potent vaccine against HPV, a sexually transmitted disease that can cause cervical cancer. But until recently, cost and production constraints limited its reach. Merck has now committed more than $1 billion to expand capacity, with a focus on underserved countries. Merck more than doubled global supply of Gardasil between 2017 and 2020 and is on track to do so again by 2023.

Change the World

This year’s Fortune 500 marks the 68th running of the list.

F500-2022-071-Merck

Pharmaceutical company Merck fell six spots on the list in its first year with CEO Robert Davis at the helm. But that modest slide masks a successful year in which profits jumped 85%, to $13 billion. Excluding revenue from Organon, the women’s health company whose spinoff was completed in June 2021, Merck’s sales overall increased 17%, including a 20% gain for the company’s hallmark cancer drug Keytruda and a 44% increase in sales for HPV vaccine Gardasil. Merck also registered nearly $1 billion in sales for molnupiravir, an oral antiviral treatment for COVID that received emergency use authorization from the FDA in December 2021.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

WMAC 2021-37-Merck

Our 2021 list of the 100 best companies to work for, as ranked by their employees. See which companies made the list.

100 Best companies-100-Merck

New to our list this year, this 130-year-old pharma giant has long devoted itself to the mission: “Save and improve lives.” Though Merck shelved its own vaccine development, President Biden announced in March that the company would help produce J&amp;J’s one-shot COVID vaccine. <a href="https://fortune.com/longform/fortune-500-black-ceos-business-history/">When current CEO Ken Frazier departs</a> at the end of June, CFO Robert Davis will take the reins. Employees say that during a difficult year, it meant a lot that Merck managed to increase benefits to employees. That included the addition of “LifeCare” specialists who can provide help in hiring a nanny or search for virtual tutors to support e-learning.The company has “stepped up,” notes an employee.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

G500-2021-232-Merck

<span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;Merck spent much of 2020 developing and testing two COVID-19 vaccine candidates but abandoned the projects in January. The company said in March that it would support the manufacturing and supply of Johnson &amp; Johnson’s COVID-19 vaccine instead. Merck’s worldwide sales increased 2% to $48 billion last year, led by a 30% increase in revenue ($14.4 billion) from its flagship cancer drug Keytruda. Despite the sales growth, Merck saw a 28% decrease in net income in 2020 compared with the prior year. And the numbers in 2021 aren’t exactly flashing green—at least so far: First-quarter sales were flat, and profit declined because of the continuing effects of the pandemic as well as increased competitive pressures for key Merck products. One more challenge for the venerable drugmaker: In June, longtime CEO Ken Frazier steps down after a stellar decade-long run leading the company. He will hand the reins to CFO Robert Davis.&quot;}" data-sheets-userformat="{&quot;2&quot;:14721,&quot;3&quot;:{&quot;1&quot;:0},&quot;10&quot;:2,&quot;11&quot;:4,&quot;14&quot;:{&quot;1&quot;:2,&quot;2&quot;:0},&quot;15&quot;:&quot;Calibri&quot;,&quot;16&quot;:11}">Merck spent much of 2020 developing and testing two COVID-19 vaccine candidates but abandoned the projects in January. The company said in March that it would support the manufacturing and supply of Johnson &amp; Johnson’s COVID-19 vaccine instead. Merck’s worldwide sales increased 2% to $48 billion last year, led by a 30% increase in revenue ($14.4 billion) from its flagship cancer drug Keytruda. Despite the sales growth, Merck saw a 28% decrease in net income in 2020 compared with the prior year. And the numbers in 2021 aren’t exactly flashing green—at least so far: First-quarter sales were flat, and profit declined because of the continuing effects of the pandemic as well as increased competitive pressures for key Merck products. One more challenge for the venerable drugmaker: In June, longtime CEO Ken Frazier steps down after a stellar decade-long run leading the company. He will hand the reins to CFO Robert Davis.

These companies foster supportive cultures, where employees find opportunities for growth with help from their colleagues.

Best Large Workplaces New York 2021-Merck

Employees say: 
 
“Sense of approachability to direct management and genuine concern they show for both work and family life. The encouragement to learn and develop talents and abilities is a consistent focus.”

The best U.S. biotechnology and pharmaceutical companies, as ranked by their employees in the past year.

Best Workplaces Biotech Pharma 2021-Merck & Co

Employees say:  
 
“Benefits increased this year in response to the pandemic and I feel incredibly supported - child care, elder care, mental health support and more.” 
 
Read Great Place to Work review .

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-65-Merck

We surveyed tens of thousands of employees to create this list of millennials’ favorite workplaces.

Best Large Workplaces Millennials 2021-Merck

Employees say: 
 
“I appreciate the co-learning attitude within this company. Even though I might be younger and newer, I have the ability to make an impact and have a voice within the group.”

100 Best Large Workplaces for Millennials

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-Featured Image-Logo-2020

The pharma giant had a banner year in 2019, climbing 29 slots on the Global 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. In the race to find a vaccine for COVID-19, Merck has adopted a slow pace compared to others in the industry. Rather than tout the company’s progress, CEO Kenneth Frazier has instead criticized industry “hype” and has warned that the process for developing an effective vaccine could take years

This year's Fortune 500 marks the 66th running of the list.

F500-2020-069-Merck

The pharma giant had a banner year in 2019, climbing seven slots on the Fortune 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. More recently, Merck has been notably quiet in medical chatter about the novel coronavirus. But executives on a late April earnings call announced that the company has teams scanning its portfolio of antiviral candidates and vaccine assets for potential treatments.

As we face unprecedented collective challenges, cooperation has become a business superpower.

53.CTW20.Merck

Merck has doubled down on “impact” investing—taking stakes in smaller companies that aim to generate a measurable social good. Its portfolio currently commits about $39 million to entities working on projects including diagnostics, drug and vaccine R&amp;D, and health infrastructure. It’s a future play with present benefits: Merck estimates more than 9 million people benefited from its impact portfolio in 2019.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here’s our look at 57 companies that do well by doing good.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Change The World

Impact Segment

Sector

Best Workplaces For Parents

Founded

Sites

Industry Vertical

Best Companies

Rank last year

Years on list

U.S. employees

U.S. job openings

Year founded

Benefits

Subsidized childcare

Compressed work weeks

Option to work remotely

Minimum requirement in-office attendance (days per week)

Mental health coverage

Free mental health sessions (per year)

Free backup childcare time off (days)

Maximum $ amount covered for fertility services

Fully paid maternal leave (days)

Fully paid paternal leave (days)

Fully paid adoptive leave (days)

Maternal leave in addition to regular time off (days)

Paid days off for volunteering

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Best Workplaces In New York

Best Workplaces In Biopharma

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

New Jersey–based Merck was founded in 1891 as the American affiliate of a German parent. Today, as a stand-alone company, it is one of the world’s biggest pharmas by revenue. It has produced numerous blockbuster medications, including the cancer treatment branded as Keytruda, which was the world’s bestselling drug in 2023, earning Merck $25 billion that year. Other high-profile medications have included diabetes treatments and anti-HIV drugs. Merck produces vaccines and has a large animal medicine business as well as a services segment whose offerings include analytics and clinical services.

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Merck (U.S.) (MRK): Company Profile, Stock Price, News, Rankings

legacy

Merck (U.S.)

merck (u.s.)

Thank you for standing by. Welcome to the Merck and Company, Inc. Rathaway, New Jersey, USA Quarter One Sales and Earnings Conference Call. At this time, all participants are in a listen only mode until the question and answer session of today's conference. This call is being recorded.

If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.

Thank you, Dustin, and good morning, everyone. Welcome to the first quarter twenty twenty five conference call for Merck and Company Incorporated, Rahway, New Jersey, USA. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer Caroline Litchfield, Chief Financial Officer and Doctor. Dean Lee, President of Research Labs. Before we get started, I'd like to point out that we have items in our GAAP results such as acquisition related charges, restructuring costs and certain other items that we have excluded from our non GAAP results.

There is a reconciliation in our press release. I will also remind you that some of the statements that we make today may be considered forward looking statements within the meaning of the Safe Harbor provision of The U. S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties.

If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward looking statements. Our SEC filings, including Item 1A and the twenty twenty four ten ks, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward looking statements made this morning. Merck and Company, Inc. Broadway, New Jersey, USA undertakes no obligation to publicly update any forward looking statements. During today's call, a slide presentation will accompany our speakers' prepared remarks.

These slides, along with the earnings release, today's prepared remarks and our SEC filings are all posted to the Investor Relations section of our company's website. With that, I'd like

Thank you, Peter. Good morning and thank you for joining today's call. Our company made strong progress to start the year with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline. We're working with focus and urgency to both realize the full potential of our near term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of the patients we serve and drive future value creation for all of our stakeholders.

In what is a dynamic global environment, we continue to work with regulators and policymakers around the world to tackle some of the biggest health challenges and ensure patient and customer access to our lifesaving and life improving medicines and vaccines. Over the last few years, we've been evolving our supply chain strategy in an effort to better balance our manufacturing footprint, which aligns well with the new administration's efforts to regrow The U. S. Manufacturing base. This can be seen by our efforts beginning with the passing of the Tax Cut and Jobs Act and accelerated since the pandemic.

Of note, since 2018, we've invested $12,000,000,000 in U. S. Manufacturing and we've committed to an additional $9,000,000,000 plus for projects through 2028. Our investments are leading to more of our products for U. S.

Patients being manufactured in The U. S. As well as more opportunities for export. Turning to our first quarter results, our performance was in line with our expectations with revenue of $15,500,000,000 reflecting strength in oncology, animal health and increasingly meaningful contributions from the continued strong launches of WinRevir and Cefaxib. As we look forward, we remain confident in our outlook for improved growth in the second half of the year.

Considering the current environment, we are maintaining our full year revenue and EPS guidance excluding business development charges, which Caroline will speak to in more detail. The benefit from improved foreign exchange is offset in part by approximately $200,000,000 of expected cost from tariffs implemented to date, primarily between The U. S. And China and to a lesser degree Canada and Mexico. With respect to potential additional tariffs by The U.

S, specifically on pharmaceuticals, our global supply chain and current inventory levels put us in a good position to navigate potential near term impacts and our ongoing efforts to locate more manufacturing in The U. S. For U. S. Supply, including for the majority of our upcoming new products will help us manage over the medium and long term.

As I look at how we've started 2025, I'm proud of the continued advancement of our research efforts. Recently, we presented important Phase three data for WinRevAir in additional patient populations supporting the strong potential for this product to improve the lives of more people living with pulmonary arterial hypertension. In addition, our HIV pipeline is now coming into sharper focus with data presentations from two Phase three trials of the zolotrovir based regimens. And new clinical trial starts and regulatory submissions in oncology reinforce our belief that we are well positioned for long term leadership with the promise of helping even more patients with cancer. The success of biopharmaceutical innovation on the scale we're driving is not measured in quarters, but rather in years.

And we're seeing compelling progress on this front. Since 2021, we've nearly tripled our late phase pipeline through both the advancement of internally discovered compounds, as well as the completion of numerous important business development transactions across multiple therapeutic areas of great unmet need, including oncology, cardiometabolic, ophthalmology and immunology. Together, our efforts have resulted in an expanded late phase pipeline comprising programs having potential commercial opportunity of over $50,000,000,000 by the mid-2030s. Winrebir and Capvaxin represent the initial launches from this robust pipeline of 20 promising potential new growth drivers we expect to come to the market over the next few years, almost all of which have blockbuster potential. Looking ahead, we have a rich slate of data readouts, presentations, filings, and additional approvals.

Our pipeline includes some of the world's most scientifically advanced modalities and Dean and our research colleagues are advancing several molecules that have foundational multi indication potential in areas of significant unmet need. We've also deepened and extended our commitment to early research and development. And over the next few years expect many of these programs to advance to Phase two and to become visible to you. Thanks to the incredible efforts of our dedicated team and the strong progress we are achieving, we believe that we're well positioned to successfully navigate through the KEYTRUDA LOE period. And our work is not finished.

Science and value driven business development remains a top priority and we continue to assess opportunities with urgency and an eye toward driving near and long term growth and value creation. In summary, our results reflect the continued demand for breakthrough therapies and novel solutions that can address global health challenges. We're leveraging our scientific leadership to deliver the next wave of innovation that can save and improve lives around the world. Our commercial performance today continues to enable the advancement of our pipeline and in turn create long term value for patients, customers and shareholders. We remain confident in our strategic direction, our commitment to research and development as the source for sustainable value creation and our enduring promise to positively impact patients.

With that, I'll turn the call over to Caroline.

Thank you, Rob. Good morning. As Rob noted, first quarter performance was in line with our expectations. The fundamentals of our business remain healthy, fueled by robust global demand for our innovative portfolio. We are confident in our ability to deliver on the promise of today, while we make strategic investments to enable the innovations of tomorrow, leveraging leading edge science to save and improve lives around the world.

Now turning to our first quarter results. Total company revenues were $15,500,000,000 a decrease of 2%, or an increase of 1% excluding the impact of foreign exchange. As expected, results were impacted by a decline in sales of Gardasil in China of approximately $1,100,000,000 reducing growth excluding foreign exchange by seven percentage points. Excluding these sales and the impact from foreign exchange, global growth was 8%, primarily driven by new products WinRevare and Capfaxiv, as well as strength in oncology and animal health. The following revenue comments will be on an ex exchange basis.

In oncology, sales of Keytruda grew 6% to $7,200,000,000 Global growth was driven by increased uptake from earlier stage cancers and robust demand from metastatic indications. In the earlier stage setting, growth was driven by increased utilization in resectable triple negative breast cancer, renal cell carcinoma, and non small cell lung cancer. In metastatic disease, we saw increased use of Keytruda in combination with PADCEF in first line locally advanced urothelial cancer, as well as Keytruda in combination with chemotherapy in first line endometrial cancer. In The US, as previously communicated, growth was negatively impacted by approximately $250,000,000 due to the timing of wholesaler purchases. Our broad oncology portfolio achieved strong growth, driven by Wellyrig, with sales increasing 63 percent to $137,000,000 due to increased use in certain patients with previously treated advanced renal cell carcinoma in The U.

S. Welireg is now the market leader in the treatment of patients with advanced renal cell carcinoma following prior therapies. In vaccines, GARDASIL sales were $1,300,000,000 a decrease of 40% driven by China, where we see elevated channel inventories and continued soft demand. In the rest of the world, growth was 16%. In The US, sales benefited from price and demand.

Outside The US and China, growth was driven by higher overall demand, including from the catch up cohort in Japan. In pneumococcal, Cavaxib sales were $107,000,000 driven primarily by demand from the retail pharmacy segment. We have made great progress in the early stages of this launch and are well positioned to help protect adults from invasive pneumococcal disease. Vaxnuvan's sales increased 7%, as growth from launches in international markets was partially offset by competitive pressures in The US. In cardiovascular, the strong momentum of the ongoing launch of WinRevair continues with global sales of $280,000,000 The launch continues to perform in line with our high expectations, and we remain excited about the significant benefit WinRevare is providing for patients.

Merck (U.S.) (MRK) Q1 2025 Earnings Call Transcript

Company Participants